Imidazopyrrolopyridine as inhibitors of the JAK family of kinases

US11827638B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Genesis M. Bacani · San Diego, US
• Wenying Chai · San Diego, US
• Tatiana Koudriakova · Poway, US
• Paul J. Krawczuk · San Diego, US
• Kevin D. Kreutter · Plainsboro, US
• Kristi A. Leonard · West Chester, US
• Michele C. Rizzolio · Durham, US
• Mark Seierstad · Escondido, US
• Russell C. Smith · San Diego, US
• Mark S. Tichenor · San Diego, US
• Jennifer D. Venable · Solana Beach, US
• Aihua Wang · Jamison, US

Key dates

• Filing date: Mar 16, 2021
• Grant date: Nov 28, 2023
• Expiry date: Jul 17, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.